MedWorm: Cancer & Oncology

Metformin-associated lactic acidosis in a pregnant patient

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Gynecol Obstet Invest 2008;66:138-141 (DOI:10.1159/000132463) (Source: Karger Publishers)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Non-random distribution and sensory functions of primary cilia in vascular smooth muscle cells

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Kidney Blood Press Res 2008;31:171-184 (DOI:10.1159/000132462) (Source: Karger Publishers)

Association of insulin resistance with de novo coronary stenosis after percutaneous coronary artery intervention in hemodialysis patients

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Nephron Clin Pract 2008;109:c9 (DOI:10.1159/000132391) (Source: Karger Publishers)

The genetics of carotid dissection: meta-analysis of a mthfr/c677t common molecular variant

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Cerebrovasc Dis 2008;25:561-565 (DOI:10.1159/000132202) (Source: Karger Publishers)

Head and neck cancer cell lines are resistant to mitochondrial-depolarization-induced apoptosis

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

ORL 2008;70:257-263 (DOI:10.1159/000133280) (Source: Karger Publishers)

Analysis of life-threatening complications of deep neck abscess and the impact of empiric antibiotics

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

ORL 2008;70:249-256 (DOI:10.1159/000132094) (Source: Karger Publishers)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Efficacy of unilateral stenting in idiopathic intracranial hypertension with bilateral venous sinus stenosis

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Eur Neurol 2008;60:47-48 (DOI:10.1159/000131712) (Source: Karger Publishers)

Subacute combined degeneration of the cord: putnam-dana syndrome

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Eur Neurol 2008;60:53-56 (DOI:10.1159/000131715) (Source: Karger Publishers)

The doctrine of signatures

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Eur Neurol 2008;60:51-52 (DOI:10.1159/000131714) (Source: Karger Publishers)

Spigc news

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Eur Surg Res 2008;40:368 (DOI:10.1159/000134084) (Source: Karger Publishers)

Neuroimage: giant intracranial lipoma with extracranial extension

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Eur Neurol 2008;60:49-50 (DOI:10.1159/000131713) (Source: Karger Publishers)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Assessment of vocal capacity of finnish university students

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Folia Phoniatr Logop 2008;60:199-209 (DOI:10.1159/000133651) (Source: Karger Publishers)

Long-term outcome after combined radiochemotherapy for anal cancer -- retrospective analysis of efficacy, prognostic factors, and toxicity

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Onkologie 2008;31:251-257 (DOI:10.1159/000121362) (Source: Karger Publishers)

Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase i study of the arbeits gemeinschaft internistische onkologie (aio)

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Onkologie 2008;31:237-241 (DOI:10.1159/000122029) (Source: Karger Publishers)

Long-term survival in stage iv melanoma after repetitive surgical therapy

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Onkologie 2008;31:259-261 (DOI:10.1159/000121409) (Source: Karger Publishers)

Perforation of the superior vena cava -- a rare complication of central venous catheters

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Onkologie 2008;31:262-264 (DOI:10.1159/000122071) (Source: Karger Publishers)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Mitomycin c in the treatment of gastrointestinal tumours: recent data and perspectives

Karger Publishers — Sat, 17 May 2008 14:37:34 +0100

Onkologie 2008;31:271-281 (DOI:10.1159/000122590) (Source: Karger Publishers)

Review finds in favor of mri screening for breast cancer

MedWire News - Breast Cancer — Sat, 17 May 2008 14:04:53 +0100

There is some evidence that screening programs for women at very high risk for breast cancer would be improved by complementing mammography with magnetic resonance imaging, say the authors of a review. (Source: MedWire News - Breast Cancer)

Risk for urologic cancer linked to risk for colorectal cancer

Medscape Hematology-Oncology Headlines — Sat, 17 May 2008 12:19:41 +0100

Patients with renal pelvis and ureteral cancers have an increased risk for colorectal cancer, and in turn, a history of colorectal cancer increases the risk for renal pelvis and ureteral cancers. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Ning wong of fox chase cancer center receives asco cancer foundation career development award

Cancer / Oncology News From Medical News Today — Sat, 17 May 2008 12:00:00 +0100

The American Society of Clinical Oncology Cancer Foundation has selected Yu-Ning Wong, M.D., M.S.C.E., of Fox Chase Cancer Center, as one of 13 clinicians to receive a 2008 Career Development Award. Career Development Awards are presented to physicians in their second, third or fourth year as full-time faculty members in an academic setting. This award marks the third time ASCO has honored Wong's accomplishments since she began her professional career in oncology in 2002. (Source: Cancer / Oncology News From Medical News Today)

Bone drug could help prevent the spread of breast cancer

Breast Cancer News From Medical News Today — Sat, 17 May 2008 08:00:00 +0100

Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.Bones are common sites for the spread, or metastasis, of breast cancer. Scientists here found that women treated for stage II/III breast cancer who also received a bone strengthening drug were less likely to have breast tumor cells growing in their bones after three months. (Source: Breast Cancer News From Medical News Today)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

New treatment implications for ovarian cancer unveiled

Cancer / Oncology News From Medical News Today — Sat, 17 May 2008 08:00:00 +0100

New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15,000 lives nationwide this year, with 480 in New Jersey. (Source: Cancer / Oncology News From Medical News Today)

Memory pharmaceuticals highlights progress with key programs at its r&d day

Cancer / Oncology News From Medical News Today — Sat, 17 May 2008 07:00:00 +0100

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist program, and separately confirmed its 2008 development goals for its pipeline. (Source: Cancer / Oncology News From Medical News Today)

Rosetta genomics to present multiple posters at the 44th annual meeting of the american society of clinical oncology (asco)

Cancer / Oncology News From Medical News Today — Sat, 17 May 2008 07:00:00 +0100

Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois. Presented posters: 1. (Source: Cancer / Oncology News From Medical News Today)

Significant anti-tumor activity of nktr-102 in patients with refractory solid tumors; interim data published in asco 2008 proceedings

Cancer / Oncology News From Medical News Today — Sat, 17 May 2008 07:00:00 +0100

Nektar Therapeutics (Nasdaq: NKTR) announced initial results from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors. The study also demonstrates that Nektar's small molecule PEGylation technology produced an increase in SN38 exposure that was up to six-fold higher than the exposure previously reported with irinotecan at equivalent doses. (Source: Cancer / Oncology News From Medical News Today)

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

Cancer — Sat, 17 May 2008 04:00:00 +0100

The combination of gemcitabine and docetaxel has demonstrated promise in sarcomas diagnosed in adults. In the current study, the toxicity and efficacy of this combination were evaluated in pediatric sarcomas.A retrospective case review of 22 patients with recurrent or refractory bone or soft-tissue sarcomas who received gemcitabine (at a dose of 675 mg/m2 intravenously on Days 1 and 8) and docetaxel (at a dose of 75-100 mg/m2 intravenously on Day 8) was undertaken.The patients (ages 8-23 years) received a total of 109 courses of chemotherapy (median, 4 courses; range, 1-13 courses). Seventeen patients had osteosarcoma, 2 patients had Ewing sarcoma family of tumors (ESFT), 1 patient had a malignant fibrous histiocytoma (MFH), 1 patient had a chondrosarcoma, and 1 patient had an undifferentiated sarcoma. Of the 14 patients evaluable for response, the patient with an MFH achieved a complete response (CR), 3 patients with osteosarcoma achieved a partial response (PR), and 2 patients (1 with ESFT and 1 with osteosarcoma) had stable disease (SD). The overall objective response (CR + PR) rate was 29%. Median duration of response (CR + PR + SD) was 4.8 months (range, 1.6-13 months). The toxicity was manageable and consisted primarily of thrombocytopenia and neutropenia.In the current study, gemcitabine in combination with docetaxel was found to be well tolerated and demonstrated antitumor activity in children and adolescents with recurrent or refractory osteosarcoma and MFH. Further evaluation of this drug combination is warranted in these patients. Cancer 2008. © 2008 American Cancer Society. (Source: Cancer)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia - a comparative study of four differently designed, high resolution microarray platforms

Genes, Chromosomes and Cancer — Sat, 17 May 2008 04:00:00 +0100

Screening for gene copy-number alterations (CNAs) has improved by applying genome-wide microarrays, where SNP arrays also allow analysis of loss of heterozygozity (LOH). We here analyzed 10 chronic lymphocytic leukemia (CLL) samples using four different high-resolution platforms: BAC arrays (32K), oligonucleotide arrays (185K, Agilent), and two SNP arrays (250K, Affymetrix and 317K, Illumina). Cross-platform comparison revealed 29 concordantly detected CNAs, including known recurrent alterations, which confirmed that all platforms are powerful tools when screening for large aberrations. However, detection of 32 additional regions present in 2-3 platforms illustrated a discrepancy in detection of small CNAs, which often involved reported copy-number variations. LOH analysis using dChip revealed concordance of mainly large regions, but showed numerous, small nonoverlapping regions and LOH escaping detection. Evaluation of baseline variation and copy-number ratio response showed the best performance for the Agilent platform and confirmed the robustness of BAC arrays. Accordingly, these platforms demonstrated a higher degree of platform-specific CNAs. The SNP arrays displayed higher technical variation, although this was compensated by high density of elements. Affymetrix detected a higher degree of CNAs compared to Illumina, while the latter showed a lower noise level and higher detection rate in the LOH analysis. Large-scale studies of genomic aberrations are now feasible, but new tools for LOH analysis are requested. © 2008 Wiley-Liss, Inc. (Source: Genes, Chromosomes and Cancer)

Breast cancer screening: evidence for false reassurance?

International Journal of Cancer — Sat, 17 May 2008 04:00:00 +0100

Tumour stage distribution at repeated mammography screening is, unexpectedly, often not more favourable than stage distribution at first screenings. False reassurance, i.e., delayed symptom presentation due to having participated in earlier screening rounds, might be associated with this, and unfavourably affect prognosis. To assess the role of false reassurance in mammography screening, a consecutive group of 155 breast cancer patients visiting a breast clinic in Rotterdam (The Netherlands) completed a questionnaire on screening history and self-observed breast abnormalities. The length of time between the initial discovery of breast abnormalities and first consultation of a general practitioner ("symptom-GP period") was compared between patients with ("screening group") and without a previous screening history ("control group"), using Kaplan-Meier survival curves and log-rank testing. Of the 155 patients, 84 (54%) had participated in the Dutch screening programme at least once before tumour detection; 32 (38%) of whom had noticed symptoms. They did not significantly differ from control patients (n = 42) in symptom-GP period (symptom-GP period [ge]30 days: 31.2% in the symptomatic screened group, 31.0% in the control group; p = 0.9). Only 2 out of 53 patients (3.8%) with screen-detected cancer had noticed symptoms prior to screening, reporting symptom-GP periods of 2.5 and 4 years. The median period between the first GP- and breast clinic visit was 7.0 days (95% C.I. 5.9-8.1) in symptomatic screened patients and 6.0 days (95% C.I. 4.0-8.0) in control patients. Our results show that false reassurance played, at most, only a minor role in breast cancer screening. © 2008 Wiley-Liss, Inc. (Source: International Journal of Cancer)

Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study

Psycho-Oncology — Sat, 17 May 2008 04:00:00 +0100

Objective: The present study has three aims: first, to evaluate the psychometric properties of the Dutch version of the CARS (CARS-DLV). Second, to measure the prevalence of concerns about disease recurrence in former breast cancer patients and identify potential predictors and third, to establish how fear of recurrence was effecting quality of life.Methods: A prospective study was carried out on breast cancer patients (n=136) who had undergone curative treatment. Eligible patients completed an extensive questionnaire consisting of the CARS (fear of recurrence), HADS (anxiety and depression), BPI (pain), RAND (quality of life), LOT (optimism) and the PCS (catastrophzing).Results: This study confirmed the good internal consistency, test-retest stability and construct validity of the CARS (Dutch Language version). Moderate to high levels of fear of disease recurrence were found in 56% of 136 breast cancer survivors. Worries about health and death were the most prominent. Pain was a strong predictor of overall fear and of fear on the four sub domains of the CARS. The prevalence of fear decreased significantly with age. Education level, living arrangements and time since the last treatment did not predict the prevalence of overall fear. Fear of recurrence was negatively correlated with quality of life.Conclusion: The CARS-DLV proved to be a valuable instrument to measure women's' concerns about breast cancer recurrence. More than half of former breast cancer patients indicated moderate to severe concerns about disease recurrence. Health and death worries were the most prominent. The levels of worry were independent of the time since diagnosis. Copyright © 2008 John Wiley & Sons, Ltd. (Source: Psycho-Oncology)

Act now to increase funding for nih and nsf!!

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 22:12:00 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

M. D. Anderson News Release 05/15/08 Celecoxib, the anti-inflammatory medication also known by the trade name Celebrex, has proven to be safe and reduces a specific proliferation measurement of precancerous lesions in the lung, according to a study from The University of Texas M. D. Anderson Cancer Center. This finding demonstrates the significance of COX-2 inhibition toward preventing lung cancer in individuals at higher risk of developing the disease. (Source: M. D. Anderson Cancer Center - News Releases)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Drug therapy to bolster immune system cells found effective toward childhood cancer

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

Combination could help children fight cancer without additional harsh therapiesM. D. Anderson News Release 05/15/08 Researchers from The University of Texas M. D. Anderson Cancer Center have found a possible approach to therapy that may make cancer cells more sensitive to attack by immune system cells while making the immune system cells more powerful. (Source: M. D. Anderson Cancer Center - News Releases)

M. d. anderson nurses find empowerment in pacts

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

Ad hoc, Multidisciplinary Teams See Major Growth in ParticipationM. D. Anderson News Release 05/15/08 According to nurse-researchers at The University of Texas M. D. Anderson Cancer Center in Houston, participation among nurses in the institution's unique Professional Action Coordinating Teams (PACTs) has increased 50 percent in one year. (Source: M. D. Anderson Cancer Center - News Releases)

Study takes a step toward better defining fatigue

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

M. D. Anderson Study Identifies Common Threads Among Cancer Patients Receiving Radiation TherapyM. D. Anderson News Release 05/15/08 In an effort to better define and ultimately address fatigue more effectively, a qualitative study from The University of Texas M. D. Anderson Cancer Center has identified three primary themes - loss of strength or energy, major effects of fatigue and associated sensations - among patients being treated with standard radiation therapy. (Source: M. D. Anderson Cancer Center - News Releases)

Dan l. duncan family foundation gives m. d. anderson its largest gift aimed solely at preventing cancer

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

$35 Million Donation Establishes the Dan Duncan Family Institute for Cancer Prevention and Risk Assessment at M. D. AndersonM. D. Anderson News Release 05/15/08 The Dan L. Duncan Family Foundation has given The University of Texas M. D. Anderson Cancer Center $35 million-the institution's largest gift to the cancer prevention program and its second-largest gift in its 67-year history. The funds will be used to establish the Dan Duncan Family Institute for Cancer Prevention and Risk Assessment. (Source: M. D. Anderson Cancer Center - News Releases)

New drug combination brings one-two punch against acute leukemia

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

M. D. Anderson News Release 05/16/08 Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation. (Source: M. D. Anderson Cancer Center - News Releases)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Researchers expand natural killer cells in cord blood to fight leukemia

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

M. D. Anderson News Release 05/16/08 Researchers from The University of Texas M. D. Anderson Cancer Center have found a therapy that effectively kills human leukemia cells in mice using natural killer (NK) cells from umbilical cord blood. (Source: M. D. Anderson Cancer Center - News Releases)

Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy

M. D. Anderson Cancer Center - News Releases — Fri, 16 May 2008 16:43:04 +0100

First positive findings in breast cancer for this class of drugsM. D. Anderson News Release 05/15/08 Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)

Prostate cancer risk gene combinations vary between ethnic groups

MedWire News - Prostate Cancer — Fri, 16 May 2008 16:33:42 +0100

Scientists have identified variant gene combinations that increase the likelihood for prostate cancer, and found that the risk associated with the different combinations varies between Hispanic White and non-Hispanic White men. (Source: MedWire News - Prostate Cancer)

Prostate cancer risk gene combinations vary between ethnic groups

MedWire News - Oncology — Fri, 16 May 2008 16:33:41 +0100

Nccn non-small cell lung cancer guidelines update

Medscape Hematology-Oncology Headlines — Fri, 16 May 2008 16:00:00 +0100

Review how new NCCN updates will impact the management of non-small cell lung cancer. (Source: Medscape Hematology-Oncology Headlines)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Can opiates be administered by nebulizer?

Medscape Hematology-Oncology Headlines — Fri, 16 May 2008 15:44:18 +0100

Some clinicians are using nebulized morphine to treat pain and breathlessness in patients with COPD and CHF, but is there evidence to back that up? Medscape Pharmacists (Source: Medscape Hematology-Oncology Headlines)

Studies examine ultrasounds for breast cancer detection, teen exercise on cancer risk

Breast Cancer News From Medical News Today — Fri, 16 May 2008 15:00:00 +0100

Using ultrasounds in addition to mammograms is more effective at detecting breast cancer than only using mammograms, according to a study published Wednesday in the Journal of the American Medical Association, USA Today reports. (Source: Breast Cancer News From Medical News Today)

Avastin improves brain cancer survival

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 14:12:00 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Monmouth medical center brain tumor center hosts celebration of survival

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 14:12:00 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Dach1 used to block metastasis in breast cancer cells

MedWire News - Breast Cancer — Fri, 16 May 2008 14:08:57 +0100

US researchers have used the cell-fate determination factor DACH1 to block oncogene-dependent tumor metastasis in breast epithelial cells. (Source: MedWire News - Breast Cancer)

MedWorm Sponsored Message: Find out how you can get your message across here by sponsoring this MedWorm news feed.

Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 13:28:42 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 13:28:42 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Regional hypoxia in glioblastoma multiforme quantified with [18f]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 13:28:42 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

Safety of anticoagulation use and bevacizumab in patients with glioma

Clinical Trials And Noteworthy Treatments For Brain Tumors — Fri, 16 May 2008 13:28:42 +0100

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)